Analysts have lifted their Fair Value estimate for 10x Genomics from about US$62.13 to about US$75.67, a change of roughly 22% in the latest round of models. Much of this reset in price targets ties back to Street commentary around AI driven demand, interest in the Atera spatial biology platform, and the balance between newer offerings and the established single cell business. As you read on, you will see how these moving parts fit together and what to watch as the 10x Genomics story continues to evolve.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Several firms have lifted valuation frameworks on 10x Genomics materially, with Barclays moving its target from US$52 to US$110 and Canaccord from US$60 to US$100. This points to increased confidence in the company's long term opportunity set.
-
Argus, with a US$110 target, highlights interest in the newly launched Atera spatial biology platform and notes that Atera data sets can support AI model training for drug discovery, which many analysts see as a key use case for the technology.
-
Multiple updates from Piper Sandler, Stephens, Citi and others reference refreshed models that incorporate Atera demand, consumable durability and AI related life science tools themes, which collectively support higher fair value assumptions.
🐻 Bearish Takeaways
-
RBC Capital, TD Cowen, BofA, Piper Sandler and Leerink all retain more cautious ratings despite higher targets. This signals ongoing questions around execution, the maturity of the single cell franchise and how quickly Atera and spatial can contribute.
-
Barclays and BofA both comment that sector valuations appear full and already reflect optimistic Q3 and next year expectations. Any disappointment versus current AI and Atera enthusiasm could pressure how investors view 10x Genomics in the near term.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for 10x Genomics. See which could impact your investment.
How This Changes the Fair Value For 10x Genomics
-
Fair value has moved from about US$62.13 to about US$75.67, a change of roughly 22% in the updated model.
-
Revenue growth has shifted from about 8.17% to about 9.40% in the refreshed estimates.
-
Net profit margin has adjusted from about 16.01% to about 15.96% in the long-term assumptions.
-
Future P/E has changed from about 89.18x to about 105.15x in the new analysis.
-
The discount rate has moved from about 8.07% to about 8.01% in the current model.
Never Miss an Update: Follow The Narrative
Narratives link 10x Genomics' business story to a financial forecast and fair value that are kept in sync with new data. They update over time as fresh company news, analyst estimates and risk factors come through.
Head over to the Simply Wall St Community and follow the Narrative on 10x Genomics to stay up to date on:
-
How lower cost consumables, such as GEM-X Flex and Universal On Chip Multiplex, aim to drive higher reaction volumes in single cell and multiomic analysis.
-
What new platforms such as Flex v2, Visium HD extensions, Xenium RNA plus protein and the Scale Biosciences acquisition could mean for 10x Genomics' role in advanced genomics and AI supported research.
-
Which macro, pricing and product transition risks, including discounting on instruments and ongoing operating losses, could challenge the path to more stable margins and earnings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TXG .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
